Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Cardiovascular Systems's Sloan Ratio for the quarter that ended in Dec. 2022 was -9.71%.
As of Dec. 2022, Cardiovascular Systems has a Sloan Ratio of -9.71%, indicating the company is in the safe zone and there is no funny business with accruals.
Cardiovascular Systems Sloan Ratio % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cardiovascular Systems's Sloan Ratio %
For the Medical Devices subindustry, Cardiovascular Systems's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiovascular Systems's Sloan Ratio % Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cardiovascular Systems's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Cardiovascular Systems's Sloan Ratio % falls into.
Cardiovascular Systems Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Cardiovascular Systems's Sloan Ratio for the fiscal year that ended in Jun. 2022 is calculated as
Cardiovascular Systems's Net Income for the trailing twelve months (TTM) ended in Dec. 2022 was -9.658 (Mar. 2022 ) + -9.69 (Jun. 2022 ) + -10.631 (Sep. 2022 ) + -7.888 (Dec. 2022 ) = $-37.9 Mil.
Cardiovascular Systems's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2022 was -2.128 (Mar. 2022 ) + -9.829 (Jun. 2022 ) + -13.652 (Sep. 2022 ) + -3.548 (Dec. 2022 ) = $-29.2 Mil.
Cardiovascular Systems's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2022 was 3.375 (Mar. 2022 ) + 7.677 (Jun. 2022 ) + 11.338 (Sep. 2022 ) + -0.864 (Dec. 2022 ) = $21.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiovascular Systems (NAS:CSII) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Dec. 2022, Cardiovascular Systems has a Sloan Ratio of -9.71%, indicating the company is in the safe zone and there is no funny business with accruals.
Cardiovascular Systems Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Cardiovascular Systems's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Cardiovascular Systems (Cardiovascular Systems) Business Description
Cardiovascular Systems Inc is a medical technology company focused on patients with peripheral and coronary artery diseases. Its peripheral artery disease systems are catheter-based platforms used to treat plaque in leg arteries above and below the knee. The firm's orbital atherectomy systems are used in peripheral and coronary commercial applications. Its OAS products include the Diamondback 360 Peripheral and Stealth 360 systems. Sales of Peripheral OAS contribute the majority of revenue. Cardiovascular systems generate the vast majority of its revenue in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CSII has been successfully added to your 